These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 33059259)

  • 61. Estradiol Levels Are Altered in Human Immunodeficiency Virus-Infected Pregnant Women Randomized to Efavirenz-Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy.
    McDonald CR; Conroy AL; Gamble JL; Papp E; Hawkes M; Olwoch P; Natureeba P; Kamya M; Silverman M; Cohan D; Koss CA; Dorsey G; Kain KC; Serghides L
    Clin Infect Dis; 2018 Jan; 66(3):428-436. PubMed ID: 29136115
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
    Simpson KN; Baran RW; Kirbach SE; Dietz B
    Value Health; 2011 Dec; 14(8):1048-54. PubMed ID: 22152173
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1.
    Falkensammer B; Fasser W; Scherer K; Zemann A; Parson W; Ulmer H; Dierich MP; Stoiber H
    Int J Immunopathol Pharmacol; 2005; 18(1):145-54. PubMed ID: 15698519
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparative Bioavailability of Two Formulations of Biopharmaceutical Classification System (BCS) Class IV Drugs: A Case Study of Lopinavir/Ritonavir.
    Saeed AM; Schmidt JM; Munasinghe WP; Vallabh BK; Jarvis MF; Morris JB; Mostafa NM
    J Pharm Sci; 2021 Dec; 110(12):3963-3968. PubMed ID: 34530003
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice].
    Moltó J; Clotet B
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():24-6. PubMed ID: 19572441
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
    Bouazza N; Foissac F; Fauchet F; Burger D; Kiechel JR; Treluyer JM; Capparelli EV; Lallemant M; Urien S
    Antivir Ther; 2015; 20(2):225-33. PubMed ID: 25279808
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A hybrid design to optimize preparation of lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation.
    Ravi PR; Vats R; Dalal V; Murthy AN
    J Pharm Pharmacol; 2014 Jul; 66(7):912-26. PubMed ID: 24697749
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
    AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
    AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study).
    Gianotti N; Galli L; Maserati R; Sighinolfi L; Ripamonti D; Palvarini L; Lo Caputo S; Focà E; Celesia BM; Baldelli F; Sterrantino G; Lazzarin A
    New Microbiol; 2016 Oct; 39(4):290-294. PubMed ID: 27551725
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.
    Magro P; Zanella I; Pescarolo M; Castelli F; Quiros-Roldan E
    Biomed J; 2021 Mar; 44(1):43-53. PubMed ID: 33608241
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis.
    Marima R; Hull R; Penny C; Dlamini Z
    Mutat Res Rev Mutat Res; 2021; 787():108376. PubMed ID: 34083040
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children.
    Martinez BL; Riordan FA
    HIV AIDS (Auckl); 2010; 2():59-67. PubMed ID: 22096385
    [TBL] [Abstract][Full Text] [Related]  

  • 75. AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2.
    Li L; Jiang P; Hu W; Zou F; Li M; Rao T; Ruan Y; Yu W; Ning J; Cheng F
    J Transl Med; 2024 Mar; 22(1):295. PubMed ID: 38515112
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir.
    Guo W; Wong S; Pudney J; Jasuja R; Hua N; Jiang L; Miller A; Hruz PW; Hamilton JA; Bhasin S
    Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2028-32. PubMed ID: 19762785
    [TBL] [Abstract][Full Text] [Related]  

  • 77. HIV protease inhibitor attenuated astrocyte autophagy involvement in inflammation via p38 MAPK pathway.
    Chen X; Ding W; Cui X; Wei J; Zhang Y; Zhang X; Zhang T; Zhang Y
    Antiviral Res; 2022 Dec; 208():105463. PubMed ID: 36372295
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dyslipidemia and cardiovascular disease in Vietnamese people with HIV on antiretroviral therapy.
    Mizushima D; Dung NTH; Dung NT; Matsumoto S; Tanuma J; Gatanaga H; Trung NV; Kinh NV; Oka S
    Glob Health Med; 2020 Feb; 2(1):39-43. PubMed ID: 33330773
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults.
    Byakika-Kibwika P; Lamorde M; Lwabi P; Nyakoojo WB; Okaba-Kayom V; Mayanja-Kizza H; Boffito M; Katabira E; Back D; Khoo S; Merry C
    Chemother Res Pract; 2011; 2011():393976. PubMed ID: 22312553
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lopinavir Loaded Spray Dried Liposomes with Penetration Enhancers for Cytotoxic Activity.
    Maniyar M; Chandak A; Kokare C
    Infect Disord Drug Targets; 2020; 20(5):724-736. PubMed ID: 31593534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.